Piramal Pharma Limited Announces Consolidated Results for Q1FY25

Key Highlights for Q1FY25  Key Highlights for Q1FY25  Nandini Piramal, Chairperson, Piramal Pharma Limited,said, " We have had a good start to the financial year with a steady all-round performance. We delivered a healthy revenue growth accompanied by over 170bps YoY expansion in EBIDTA margin driven by favorable revenue mix and cost optimization initiatives. Our CDMO business continues to witness sustained order inflows, especially for on-patent commercial manufacturing. We are also...

Key Highlights for Q1FY25 

Nandini Piramal, Chairperson, Piramal Pharma Limited, said, "We have had a good start to the financial year with a steady all-round performance. We delivered a healthy revenue growth accompanied by over 170bps YoY expansion in EBIDTA margin driven by favorable revenue mix and cost optimization initiatives. Our CDMO business continues to witness sustained order inflows, especially for on-patent commercial manufacturing. We are also seeing good demand for our differentiated offerings with increase in customer enquiries and visits. In our CHG business, our planned expansion for inhalation anesthesia portfolio is on track and is expected to get commercialized in FY26. Our India Consumer Healthcare business is also delivering steady growth driven by power brands and strong traction in e-commerce channel.

"As a responsible organisation, we are taking good strides in our journey towards building sustainable operations. Our continuous efforts in quality and compliance bore fruits with successful closure of USFDA inspections at two of our facilities at Lexington (USA) and PPDS (Analytical Services, India).

"Historically our H2 outperforms H1, both in terms of revenue and profitability, and we expect this trend to continue in FY25. We intend to further build on to the good start that we have had to the financial year."

India Consumer Healthcare (ICH):

Q1FY25 Earnings Conference Call

Piramal Pharma Limited will be hosting a conference call for investors / analysts on 26^thJuly 2024 from 5:00 PM to 5:45 PM(IST)to discuss its Q1FY25 Results.

The dial-in details for the call are as under:

About Piramal Pharma Limited:

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments. In October 2020, PPL received a 20% strategic growth investment from the Carlyle Group. 

For more information, visit: Piramal Pharma | LinkedIn

 <sub># EIR - Establishment Inspection Report
* Includes one facility via PPL's minority investment in Yapan Bio.</sub>

Logo: https://mma.prnewswire.com/media/1855206/Piramal_Pharma_Limited_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/piramal-pharma-limited-announces-consolidated-results-for-q1fy25-302207455.html